Clinical Trial

Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.

Study acronym: PROPER2
Recruiting
View on ClinicalTrials.gov →
Summary
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \<0.70 ng/ml) after prostatectomy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-04-23; most recent amendment 2025-09-10.
Trial Details
NCT Number NCT04858880
Lead Sponsor Lund University Hospital
Conditions Prostate Cancer
Enrollment 374 participants
Start Date 2021-04-09
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2025-09-16